Current Diabetes Trials
AFREZZA™
The body’s initial response to rising blood sugar after a meal is a rapid release of insulin from the pancreas. In those with diabetes, this rapid release of insulin is limited or lost. In people with type 1 diabetes, the pancreas no longer makes insulin at all. People with type 2 diabetes are able to make insulin, but their bodies don’t respond well to it. MannKind is conducting clinical studies of an investigational ultra rapid-acting insulin that is inhaled through a palm-sized device.
MKC1106
MannKind is also conducting clinical studies of its investigational immunotherapy regimen.
For more information or to enroll, visit www.clinicaltrials.gov
